Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation

BACKGROUND: Since hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after NA cessation. However, there is still contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yandi, Li, Minghui, Ou, Xiaojuan, Zheng, Sujun, Gao, Yinjie, Xu, Xiaoyuan, Yang, Ying, Ma, Anlin, Li, Jia, Nan, Yuemin, Zheng, Huanwei, Liu, Juan, Wei, Lai, Feng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308768/
https://www.ncbi.nlm.nih.gov/pubmed/37386460
http://dx.doi.org/10.1186/s12876-023-02852-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308768/
https://www.ncbi.nlm.nih.gov/pubmed/37386460
http://dx.doi.org/10.1186/s12876-023-02852-x

Ejemplares similares